SOLIRIS (eculizumab): The first treatment specifically approved for PNH

My name is Margarita.

Margarita

I'm 36 years old — and a mother of 3.
I've had PNH for 18 years.
This is my story.
1 2 3 Next

 

After first receiving SOLIRIS®, Margarita began to notice an increase in her energy and stamina. For the first time in sixteen years, she was actually starting to feel normal. Margarita couldn't believe it — she had gone a full month without a blood transfusion.

But the best surprise came when Margarita saw her first blood counts after taking SOLIRIS. Her hematology nurse thought it must have been a mistake. Her hematocrit, which had been in the low 20s before, was at 34.

'When they finally showed me my first high blood counts, I thought I am going to frame these!'

She now has the energy to hike and swim and play with her kids.Today, Margarita is thirty-six. In the two years since starting SOLIRIS, she has only had one blood transfusion and that was due to a ruptured cyst unrelated to PNH. She now has the energy to hike and swim and play with her kids. She's going out with her friends again and even dancing. Her chores get done in a day, instead of a week. Best of all? She's no longer living in her laundry room.

 

'I finally have my life back.'

Thanks to SOLIRIS and her doctors, Margarita is presently free from transfusions and migraines. She's finally feeling like herself again.

A WORD OF THANKS
Many thanks to Margarita and the other people who have shared their very personal stories about PNH and its treatment with SOLIRIS. By reaching out, people with PNH can connect with others who have this rare, sometimes isolating, disease. Do you have PNH or know someone who does? Or are you a physician who is treating someone with PNH? In either case, you can get more information about PNH and SOLIRIS therapy by calling 1.888.SOLIRIS (1.888.765.4747).

1 2 3 Next

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References: 1. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192.